Anumana Funding, Investors & Competitors

Twin Health is a Mountain View, California-headquartered digital health company offering an AI-driven Whole Body Digital Twin platform for metabolic disorders. The system uses wearable sensors to monitor glucose, activity, and sleep, generating personalized nutrition and lifestyle plans. Clinically validated to reverse type 2 diabetes, Twin Health operates clinics in the US and India.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity’s products and services are sold worldwide, with major markets in the US, Europe, and China.

Neko Health is a health technology company developing non-invasive whole-body scanners for preventive checkups. Its flagship device captures 3D images, heart rate, blood pressure, and skin analysis in minutes at clinics or pop-ups. Stockholm-based Neko Health, founded by Spotify co-founder Daniel Ek, began operations in 2023 with pilot sites in Sweden aiming for global expansion.

XtalPi Holdings Ltd is an research platform company powered by artificial intelligence (AI) and robotics. It is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. The company combines quantum physics, AI, cloud computing, and large-scale robotics to provide research & development solutions, services, and products for pharmaceuticals, biotechnology, renewable energy, and materials industries globally. The company has single segment that is intelligent robotics solutions and drug discovery solutions (including one-stop drug discovery solutions).

Noom is a digital health platform combining psychology, AI, and human coaching for wellness goals including weight management, diabetes prevention, and stress reduction. New York City-headquartered, it secured grants from the National Institutes of Health and became the first mobile app certified by the Centers for Disease Control for diabetes prevention. Noom serves millions via app-based programs with behavioral tracking and virtual coaching sessions. Recognized by Inc and Fortune for workplace culture, it operates globally with personalized nutrition and habit-building modules.

NantOmics is a Culver City-headquartered molecular diagnostics company that develops cloud-based molecular profiling tools, including the GPS Cancer test and OncoPlexDx Targeted Proteomic panel, to guide personalized cancer treatments for patients and oncologists. As a subsidiary of NantWorks, it delivers point-of-care insights into cancer biology through quantitative protein biomarkers and genomic profiles. NantOmics supports treatment strategies in clinical settings across the United States, with headquarters in California and integration into broader precision medicine platforms.

Cult.fit is a Bangalore-headquartered health and fitness company founded in 2016. It operates over 280 gyms across 50 Indian cities, delivering trainer-led classes in yoga, dance, strength training, and cycling. The platform provides nutrition plans via EatFit cloud kitchens, mental wellness through Cult.Mind, and primary care consultations, serving 2 million monthly active users.

Iterative Health applies AI to gastrointestinal care through clinical trials and diagnostics. The healthcare technology company accelerates research to advance patient outcomes.

Welle is a digital health company based in New York providing personalized care plans to mitigate inflammation and chronic disease risks. Its platform uses at-home testing kits for biomarkers like hsCRP and offers nutrition, supplement, and lifestyle recommendations via app-based coaching. Welle targets corporate wellness programs and partners with employers in finance and tech sectors for employee health initiatives.

Evidation Health is a San Mateo-headquartered company founded in 2012 that measures health outcomes through everyday activities via its Achievement platform. The platform enables participation in research and health programs with partners in healthcare and pharmaceuticals. Evidation maintains offices worldwide and emphasizes user-controlled health data for studies beyond clinical settings.

Sword Health is a Lisbon-headquartered digital therapeutics company offering AI-guided physical therapy for musculoskeletal and pelvic floor conditions. Patients access virtual sessions via app with motion-tracking sensors and clinician oversight. The platform supports remote recovery programs for back pain, joint issues, and postpartum care.

Hippocratic AI is a San Francisco-headquartered developer of large language models optimized for non-diagnostic healthcare interactions. Its platform deploys AI agents for tasks like preoperative education, discharge instructions, and chronic disease follow-ups via phone or text. Built on a multi-agent architecture with clinician oversight, the system includes an agent marketplace for specialties such as cardiology and oncology. Health systems integrate agents into workflows for patient outreach and triage support.

Komodo Health is a San Francisco-headquartered platform that maps over 500 million patient journeys by integrating claims, clinical, and pharmacy data sources into its Healthcare Map. The system leverages AI and data science to deliver real-world evidence and market insights for life sciences companies, healthcare payers, and providers. Since its founding in 2014, it serves more than 1,500 life sciences organizations including major pharmaceutical firms in therapy development and commercialization. The company maintains a presence across the United States with additional offices in New York and Boston.

ConcertAI is a Boston-headquartered company founded in 2018 that supplies AI-powered real-world evidence platforms for oncology research. It aggregates de-identified patient data from over 2 million cancer cases across U.S. health systems and delivers analytics for clinical trial design, site selection, and regulatory submissions. The firm partners with pharmaceutical companies like Pfizer and Bristol Myers Squibb to accelerate drug development.

iCarbonX is a Beijing-headquartered developer of AI-powered digital health ecosystems combining genomic sequencing, wearable data, and machine learning for personalized wellness. The platform analyzes multi-omics data from partnerships with BGI Genomics to deliver health risk scores, disease predictions, and lifestyle recommendations via mobile apps. iCarbonX focuses on chronic disease prevention through continuous monitoring of biomarkers like blood glucose and heart rate variability.

Founded in Germany in 1972 by former IBM employees, SAP is the world’s largest provider of enterprise application software. Known as the leader in enterprise resource planning software, SAP’s portfolio also includes software for supply chain management, procurement, travel and expense management, and customer relationship management, among others. The company operates in more than 180 countries and has more than 400,000 customers, approximately 80% of which are small to medium-size enterprises.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.